The company has entered into a multi-target partnership with Sosei Group to discover, develop and commercialize compounds targeting novel G protein-coupled receptor (GPCR) targets in diabetes and metabolic diseases.
The companies have initiated a research agreement supporting the development of new AI-ECG algorithm to help identify patients who may be at risk of cardiac amyloidosis.
While showing early promise, Senolytics is a new field and most of the research is still in academic centers – most notably, the Mayo Clinic.
Bloomberg reported on Thursday that Medtronic was also open to a sale at the right price and the businesses could be valued at more than $7 billion. The two businesses were also drawing interest from private-equity firms, according to the report.
In a head-to-head comparison trial, BeiGene’s Brukinsa (zanubrutinib) bested Janssen’s Imbruvica (ibrutinib) in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL).
ReutersThe U.S. Food and Drug Administration’s panel of outside experts did not lend its support to Cytokinetics Inc.’s heart drug, citing insufficient data on safety and efficacy.
Multimillion-dollar gene therapies being tested for sickle cell disease will be cost-effective in the United States if health disparities tied in part to decreased access to healthcare are taken into account, researchers said at a meeting of blood-disease specialists.
A combination of Moderna’s melanoma vaccine and Merck’s immunotherapy Keytruda cut the risk of skin cancer’s recurrence or death by 44% compared with Keytruda alone in a mid-stage trial.
Even as their clients are trying to make clinical trials more diverse and equitable, agencies are continuing their DE&I efforts to build a culture where diverse talent is welcomed.
Co-developed by J&J’s Janssen and AbbVie’s Pharmacyclics, ibrutinib stood out across several presentations at the 64th American Society of Hematology (ASH) annual meeting Saturday and Sunday.
